In Silico Adme and Toxicity Studies of Derivative Phthalimide Compounds as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor
Abstract
Phthalimide derivate compounds was reported as a new class of nonnucleoside reverse tranckriptase inhibitors. The aim of this research is to determine the prediction of absorption, distribution, metabolism, and excretion (ADME) as well as the toxicity test of phthalimide-derived compounds which have the best potential as HIV-1 reverse transcriptase enzyme inhibitors. This study used an in silico approach to predict oral bioavailability and toxicity. The prediction of the ADME in this study using SwissADME which is run online where thirty-three phthalimide derivate compounds have molecular weight, hydrogen donor and acceptor bond, and log P that meet the criteria of Lipinski Rules. Prediction of toxicity in this study using in silico method with Toxtree v1.60 and it is known that phthalimide derivate compounds are not carcinogenic and mutagenic.
References
Daina A, Michielin O, Zoete V. (2017). SwissADME: a Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. PubMed Scientific reports. Vol 7: 42717.
Darvas, Ferenc & Dorman, Gyorgy & Papp, Ákos. (2000). Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries. Journal of Chemical Information and Computer Sciences. Volume 40. 314-22.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Advance Drug Delivery. Vol 46 (1-3): 3–26.
Listyani Tiara A. (2019). Molecular Docking Analysis of Derivate Phthalimide Compounds as Non-Nucleosida HIV-1 Reverse Transcriptase Inhibitor. Jurnal Farmasi Indonesia, hlm 123-134.
Mohamed G. Atta, Sophie De Seigneux and Gregory M. Lucas. (2018). Clinical Pharmacology in HIV Therapy. Clinical Journal American Society of Nephrology. CJN 02240218.
Neelottama Kushwaha and Darpan Kaushik. (2016). Recent Advances and Future Prospects of Phthalimide Derivatives. Journal of Applied Pharmaceutical Science. Vol 6(03). 159-171.
Ruswanto et all. (2018). Desain dan Studi In Silico Senyawa Derivat Kuwanon-H sebagai Kandidat Obat Anti-HIV. Jurnal Kimia VALENSI: Jurnal Penelitian dan Pengembangan Ilmu Kimia, 4(1), Mei 2018, 57-66,
Samee W, Ungwitayatorn J, Matayatsuk C, Pimthon J. (2004). 3D-QSAR Studies on Phthalimide Derivatives as HIV-1 Reverse transcriptase Inhibitors. ScienceAsia 30 (2004): 81-88.
Siswandono, dan Bambang Soekardjo. 2000. Kimia Medisina edisi 1. Surabaya : Airlangga University. Hal 190.
Talele TT, Khedkar SA and Rigby AC. 2010. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Current topics in medicinal chemistry. 10(1) : 127-41
Valerie A. Braz, Mary D. Barkley, Rebecca A. Jockusch, and Patrick L. Wintrode. 2010. Binding of the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz to HIV-1 Reverse Transcriptase Monomers and Dimers. PMC Biochemistry. 49(49). 10565-10573.
